Latent SpaceApr 21, 2026, 00:17 UTC+8

Training Transformers to Address the 95% Failure Rate in Cancer Trials — Noetik

🔬 Training Transformers to solve 95% failure rate of Cancer Trials — Ron Alfa & Daniel Bear, Noetik

Noetik uses TARIO-2 to predict tumor spatial transcriptomics, targeting a 95% cancer-trial failure rate. GSK signed a $50M technology deal, and TARIO-2 predicts a ~19,000-gene spatial map from routine H&E assays. The key issue is patient-tumor-treatment matching, not the claim that AI cures cancer.

Why it matters: HKR-H/K/R pass: the hook ties 95% cancer-trial failure to transformer matching, with TARIO-2 predicting ~19k spatial genes from H&E and a $50M GSK deal. Vertical AI productization, not a general model release, keeps it at featured threshold.

Read the original ↗Export Markdown

Take

Noetik’s sharp edge is not the 95% trial-failure headline; it is compressing scarce spatial transcriptomics into the H&E workflow pharma already uses. TARIO-2 predicts a roughly 19,000-gene spatial map from routine H&E slides, while the article says about 0% of standard-care cancer patients get whole-plex spatial transcriptomics. That is the credible reason behind GSK’s $50M technology deal.

I don’t buy the “solve cancer trial failure” framing. Better patient-tumor-treatment matching helps stratification, but it does not erase clinical endpoints, toxicity, or enrollment noise. Compared with Isomorphic or Boltz-style discovery tooling, Noetik’s licensing path smells closer to trial-design infrastructure inside pharma. The catch: the long-term license terms are undisclosed, so the strength of GSK’s actual commitment is still hard to price.

Source: Latent Space · latent.space
Published: Apr 21, 2026, 00:17 UTC+8 · Apr 21, 2026